Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model

Vaz, Raquel; Sousa, Sara; Chapela, Diana; Linde, Herma van der; Willemsen, Rob; Correia, Ana D.; Outeiro, Tiago F.; Afonso, Nuno

doi:10.1016/j.pbb.2019.172828

Cited by 20 publications

(11 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Slower speed and shorter swimming distances are similar to akinesia seen in PD patients (Makhija and Jagtap, 2014). In another study, 6-OHDA exposure to larval zebrafish reduced burst swimming (a swimming behavior for zebrafish larvae) 2 days after the exposure (Vaz et al, 2020). Plus, similar to the adult zebrafish, larval zebrafish also exhibit shorter swimming distances when exposed to 6-OHDA (Feng et al, 2014).…”

Section: -Hydroxydopamine (6-ohda)mentioning

confidence: 85%

See 1 more Smart Citation

The Promise of the Zebrafish Model for Parkinson’s Disease: Today’s Science and Tomorrow’s Treatment

et al. 2021

View full text Add to dashboard Cite

The second most prevalent neurodegenerative disorder in the elderly is Parkinson’s disease (PD). Its etiology is unclear and there are no available disease-modifying medicines. Therefore, more evidence is required concerning its pathogenesis. The use of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is the basis of most animal models of PD. MPTP is metabolized by monoamine oxidase B (MAO B) to MPP + and induces the loss of dopaminergic neurons in the substantia nigra in mammals. Zebrafish have been commonly used in developmental biology as a model organism, but owing to its perfect mix of properties, it is now emerging as a model for human diseases. Zebrafish (Danio rerio) are cheap and easy to sustain, evolve rapidly, breed transparent embryos in large amounts, and are readily manipulated by different methods, particularly genetic ones. Furthermore, zebrafish are vertebrate species and mammalian findings obtained from zebrafish may be more applicable than those derived from genetic models of invertebrates such as Drosophila melanogaster and Caenorhabditis elegans. The resemblance cannot be taken for granted, however. The goal of the present review article is to highlight the promise of zebrafish as a PD animal model. As its aminergic structures, MPTP mode of action, and PINK1 roles mimic those of mammalians, zebrafish seems to be a viable model for studying PD. The roles of zebrafish MAO, however, vary from those of the two types of MAO present in mammals. The benefits unique to zebrafish, such as the ability to perform large-scale genetic or drug screens, should be exploited in future experiments utilizing zebrafish PD models.

show abstract

Section: -Hydroxydopamine (6-ohda)mentioning

confidence: 85%

“…The induction of 6-OHDA on zebrafish stimulates the death of DA neurons and subsequent reduction of dopamine levels in the lesioned area (Vaz et al, 2020). Vijayanathan et al (2017) reported a substantial loss of DA neurons within 12 h after 6-OHDA administration.…”

Section: -Hydroxydopamine (6-ohda)mentioning

confidence: 99%

The Promise of the Zebrafish Model for Parkinson’s Disease: Today’s Science and Tomorrow’s Treatment

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Moreover, recent studies have also shown that α-syn can bind and activate MAO-B, accelerating PD progression. MAO-B inhibitors, such as l-deprenyl and rasagiline, show potential antidyskinetic and neuroprotective effects in PD zebrafish models (McKinley et al, 2005;Cronin and Grealy, 2017;Vaz et al, 2020). MAO-B inhibitors have been used clinically as an alternative to L-DOPA.…”

Section: Drug Discovery In Zebrafish Models Of Parkinson's Diseasementioning

confidence: 99%

“…Certain natural products are promising in disease treatment as they also have an effect on autophagy, apoptosis, inflammation, or oxidative stress pathways (Zhang et al, 2020;Kesh et al, 2021b;Santo et al, 2021;Wu et al, 2021). Recently, Vaz et al tested 1600 FDAapproved bioactive drugs in the 6-OHDA-induced zebrafish model and highlighted novel molecules with antiparkinsonian potential (Vaz et al, 2020). These drugs could possibly become adjuvant medicine in the future treatment of PD.…”

Section: Drug Discovery In Zebrafish Models Of Parkinson's Diseasementioning

confidence: 99%

Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery

Wang

Zhang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Neurodegenerative disease (NDD), including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, are characterized by the progressive loss of neurons which leads to the decline of motor and/or cognitive function. Currently, the prevalence of NDD is rapidly increasing in the aging population. However, valid drugs or treatment for NDD are still lacking. The clinical heterogeneity and complex pathogenesis of NDD pose a great challenge for the development of disease-modifying therapies. Numerous animal models have been generated to mimic the pathological conditions of these diseases for drug discovery. Among them, zebrafish (Danio rerio) models are progressively emerging and becoming a powerful tool for in vivo study of NDD. Extensive use of zebrafish in pharmacology research or drug screening is due to the high conserved evolution and 87% homology to humans. In this review, we summarize the zebrafish models used in NDD studies, and highlight the recent findings on pharmacological targets for NDD treatment. As high-throughput platforms in zebrafish research have rapidly developed in recent years, we also discuss the application prospects of these new technologies in future NDD research.

show abstract

“…In zebrafish, after the injection of 6-OHDA into the ventral diencephalon, a significant reduction of dopaminergic neurons and reduced swimming speed and distance travelled were observed [ 37 ]. A recent study also reported the death of DA neurons and the reduction of dopamine levels in the lesioned brain area of the 6-OHDA administrated zebrafish [ 38 ]. Similarly, the exposure of zebrafish larvae to 6-OHDA produced a reduction in dopaminergic neurons [ 39 ].…”

Section: Parkinson’s Disease Modelsmentioning

confidence: 99%

Zebrafish and Medaka: Important Animal Models for Human Neurodegenerative Diseases

Wang

Cao

2021

IJMS

View full text Add to dashboard Cite

Animal models of human neurodegenerative disease have been investigated for several decades. In recent years, zebrafish (Danio rerio) and medaka (Oryzias latipes) have become popular in pathogenic and therapeutic studies about human neurodegenerative diseases due to their small size, the optical clarity of embryos, their fast development, and their suitability to large-scale therapeutic screening. Following the emergence of a new generation of molecular biological technologies such as reverse and forward genetics, morpholino, transgenesis, and gene knockout, many human neurodegenerative disease models, such as Parkinson’s, Huntington’s, and Alzheimer’s, were constructed in zebrafish and medaka. These studies proved that zebrafish and medaka genes are functionally conserved in relation to their human homologues, so they exhibit similar neurodegenerative phenotypes to human beings. Therefore, fish are a suitable model for the investigation of pathologic mechanisms of neurodegenerative diseases and for the large-scale screening of drugs for potential therapy. In this review, we summarize the studies in modelling human neurodegenerative diseases in zebrafish and medaka in recent years.

show abstract

Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model

Cited by 20 publications

References 49 publications

The Promise of the Zebrafish Model for Parkinson’s Disease: Today’s Science and Tomorrow’s Treatment

The Promise of the Zebrafish Model for Parkinson’s Disease: Today’s Science and Tomorrow’s Treatment

Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery

Zebrafish and Medaka: Important Animal Models for Human Neurodegenerative Diseases

Contact Info

Product

Resources

About